Dr. Antoni Ribas MD Los Angeles, CA with 21+ years experience
Gender: Male Years In Practice: 21+ Phone Number:(310) 206-3928
Specialty
Hematology
General Hematology
Contact
100 Medical Plaza
#550
Los Angeles, CA 90095 Phone:(310) 206-3928 Fax: (310) 206-3928
Insurances
Aetna Choice POS II Aetna HMO Anthem Blue Access PPO Anthem Blue Preferred HMO BCBS Blue Card PPO BCBS California CaliforniaCare HMO BCBS California PPO BCBS Illinois PPO CIGNA HMO CIGNA Open Access CIGNA PPO First Health PPO Great West PPO
Health Net California Large Group PPO Health Net HMO - Employer Group HealthAmerica HealthAssurance PPO Humana ChoiceCare Network PPO Medical Mutual of Ohio SuperMed Plus Medical Mutual of Ohio SuperMed POS Multiplan PHCS PPO Multiplan PHCS PPO - Kaiser Multiplan PPO Pacificare HMO Sagamore Health Plus United Healthcare - Direct Choice Plus POS United Healthcare - Direct Options PPO
Affiliated Hospitals
UCLA Medical Center Los Angeles, CA UCLA Medical Center-Santa Monica Santa Monica, CA
Dr. Antoni Ribas's Videos
Dr. Antoni Ribas on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib
Antoni Ribas, MD, Department of Medicine, Division of Hematology-Oncology; Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), describes the unique combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, which both inhibit activating mutations in the mitogen-activated protein kinase (MAPK) pathway.
Read more at
Dr. Antoni Ribas on Combining Vemurafenib and Ipilimumab for Metastatic Melanoma
Antoni Ribas, MD, Department of Medicine, Division of Hematology-Oncology; Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), describes a phase I/II trial that plans to combine the BRAF inhibitor vemurafenib (Zelboraf) and the cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab (Yervoy) for patients with BRAF V600-mutated metastatic melanoma.
For more melanoma and skin cancer resources, visit